Welcome to our dedicated page for Biostem Tech news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on Biostem Tech stock.
BioStem Technologies reports developments tied to its regenerative medicine business, which develops, manufactures and commercializes perinatal tissue allograft products used by clinicians across wound care and other specialties. Company updates commonly cover financial results, conference calls, clinical research presentations, and product portfolio activity involving brands such as Neox, Clarix, VENDAJE and American Amnion.
BioStem news also includes governance and compliance appointments, board changes, audited financial statement publication, and integration of completed asset acquisitions that expand its surgical and wound-care product offerings. Its disclosures describe proprietary BioRetain, CryoTek and SteriTek processing technologies, AATB-accredited quality systems, and operations aligned with current Good Tissue Practices and current Good Manufacturing Processes.
BioStem Technologies (OTC:BSEM) filed a Form 10 registration statement with the U.S. SEC to register its common stock under the Exchange Act and reaffirmed its plan to seek a Nasdaq listing. The Form 10 is not yet effective, and the stock will continue trading on the OTC market until any Nasdaq uplisting.
BioStem Technologies (OTC:BSEM) announced issuance of four U.S. design patents from the USPTO covering its proprietary fenestrated human placental allograft technologies.
The patents address conformability, fluid transfer, drainage, moisture and wound management in surgical and wound care settings and expand an intellectual property portfolio of more than 100 patents and applications worldwide, supporting BioStem's regenerative medicine growth strategy.
BioStem Technologies (OTC:BSEM), a regenerative medicine company focused on perinatal tissue allograft products, announced that management will present at the Planet MicroCap Las Vegas 2026 Conference.
The presentation is scheduled for Wednesday, June 17, 2026, at 3:00 PM ET, with live and archived webcasts available on the company’s investor relations website.
BioStem Technologies (OTC:BSEM) appointed three new independent directors, Mark Glickman, Steven D. Sonenreich, and Rayna Lesser Hannaway, effective June 5, 2026. They join key board committees and bring expertise in life sciences commercialization, healthcare administration, and investment management.
Two directors resigned June 4, 2026, leaving a seven-member board as BioStem pursues growth and a potential Nasdaq uplisting.
BioStem Technologies (OTC:BSEM) entered a securities purchase agreement with its first institutional investor for a $2.5 million private placement. The deal covers 746,269 shares of common stock at $3.35 per share.
According to the company, proceeds will support working capital and general corporate purposes, strengthening its balance sheet as it advances plans for a potential Nasdaq uplisting. The agreement includes anti-dilution provisions tied to certain future offerings and requires BioStem to file a resale registration statement with the SEC. Closing is expected on or about May 22, 2026, subject to customary conditions.
BioStem Technologies (OTCQB:BSEM) announced USPTO Notices of Allowance for four U.S. design patents covering fenestrated human placental allografts and a new European patent for sterile placental allografts and proprietary processing methods.
The patents expand a portfolio of over 70 patents supporting wound care, surgical, dental, cosmetic and regenerative applications.
BioStem Technologies (OTC:BSEM) reported first quarter 2026 results and strategic updates.
Net revenue was $6.1M, mainly from Neox and Clarix, with hospitals contributing 87% ($5.4M) and physician offices $0.8M. Gross profit was $3.8M with 61% margin. Operating expenses were $12.6M; GAAP net loss was $8.8M ($0.52/share) and adjusted EBITDA was ($5.7M). Cash was $13.7M on March 31, 2026.
The company advanced integration of acquired BioTissue assets, expanded its direct sales force to 35, retired approximately $5.3M of GMA debt, completed 2024–2025 audits, and is progressing toward a planned Nasdaq uplisting. BioStem guides 2026 revenue to $25–$29M.
BioStem Technologies (OTC:BSEM) announced that company management will present at the 16th Annual LD Micro Invitational in Los Angeles, CA.
The presentation is scheduled for Monday, May 18, 2026, at 1:30 PM ET, with live and archived webcasts available on the company’s investor relations website.
BioStem Technologies (OTC: BSEM) will release first quarter 2026 financial results on Thursday, May 14, 2026 and will host a conference call and webcast at 4:30 PM ET.
The webcast will include an overview of the quarter from management. Registration and live access details are provided via a webcast link and conference call numbers.
BioStem Technologies (OTC: BSEM) appointed Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026.
Gorrell brings ~20 years of health‑law and compliance experience, will oversee legal, compliance, enterprise governance and integration of Medical Affairs, and will support BioStem’s growth and stated efforts toward a Nasdaq uplisting.